These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 32380069

  • 1. Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
    Kobbernagel HE, Buchvald FF, Haarman EG, Casaulta C, Collins SA, Hogg C, Kuehni CE, Lucas JS, Moser CE, Quittner AL, Raidt J, Rosthøj S, Sørensen AL, Thomsen K, Werner C, Omran H, Nielsen KG.
    Lancet Respir Med; 2020 May; 8(5):493-505. PubMed ID: 32380069
    [Abstract] [Full Text] [Related]

  • 2. Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia.
    Kobbernagel HE, Buchvald FF, Haarman EG, Casaulta C, Collins SA, Hogg C, Kuehni CE, Lucas JS, Omran H, Quittner AL, Werner C, Nielsen KG.
    BMC Pulm Med; 2016 Jul 22; 16(1):104. PubMed ID: 27450411
    [Abstract] [Full Text] [Related]

  • 3. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.
    Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, Bauert PA, Masters IB, Diaz A, McCallum GB, Mobberley C, Tjhung I, Hare KM, Ware RS, Chang AB.
    Lancet Respir Med; 2013 Oct 22; 1(8):610-620. PubMed ID: 24461664
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.
    Goyal V, Grimwood K, Ware RS, Byrnes CA, Morris PS, Masters IB, McCallum GB, Binks MJ, Smith-Vaughan H, O'Grady KF, Champion A, Buntain HM, Schultz A, Chatfield M, Torzillo PJ, Chang AB.
    Lancet Respir Med; 2019 Sep 22; 7(9):791-801. PubMed ID: 31427252
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial.
    Ringshausen FC, Shapiro AJ, Nielsen KG, Mazurek H, Pifferi M, Donn KH, van der Eerden MM, Loebinger MR, Zariwala MA, Leigh MW, Knowles MR, Ferkol TW, CLEAN-PCD investigators and study team.
    Lancet Respir Med; 2024 Jan 22; 12(1):21-33. PubMed ID: 37660715
    [Abstract] [Full Text] [Related]

  • 6. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
    Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, Pelle AJ, Hoogsteden HC, Aerts JG, van der Eerden MM.
    Lancet Respir Med; 2014 May 22; 2(5):361-8. PubMed ID: 24746000
    [Abstract] [Full Text] [Related]

  • 7. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
    Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T.
    Lancet; 2012 Aug 18; 380(9842):660-7. PubMed ID: 22901887
    [Abstract] [Full Text] [Related]

  • 8. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial.
    Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, Marks GB, Baraket M, Powell H, Taylor SL, Leong LEX, Rogers GB, Simpson JL.
    Lancet; 2017 Aug 12; 390(10095):659-668. PubMed ID: 28687413
    [Abstract] [Full Text] [Related]

  • 9. Reducing exacerbations in children and adults with primary ciliary dyskinesia using erdosteine and/or azithromycin therapy (REPEAT trial): study protocol for a multicentre, double-blind, double-dummy, 2×2 partial factorial, randomised controlled trial.
    Chang AB, Morgan LC, Duncan EL, Chatfield MD, Schultz A, Leo PJ, McCallum GB, McInerney-Leo AM, McPhail SM, Zhao Y, Kruljac C, Smith-Vaughan HC, Morris PS, Marchant JM, Yerkovich ST, Cook AL, Wurzel D, Versteegh L, O'Farrell H, McElrea MS, Fletcher S, D'Antoine H, Stroil-Salama E, Robinson PJ, Grimwood K.
    BMJ Open Respir Res; 2022 May 12; 9(1):. PubMed ID: 35534039
    [Abstract] [Full Text] [Related]

  • 10. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
    Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG.
    JAMA; 2013 Mar 27; 309(12):1251-9. PubMed ID: 23532241
    [Abstract] [Full Text] [Related]

  • 11. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.
    Stick SM, Foti A, Ware RS, Tiddens HAWM, Clements BS, Armstrong DS, Selvadurai H, Tai A, Cooper PJ, Byrnes CA, Belessis Y, Wainwright C, Jaffe A, Robinson P, Saiman L, Sly PD, COMBAT CF Study Group.
    Lancet Respir Med; 2022 Aug 27; 10(8):776-784. PubMed ID: 35662406
    [Abstract] [Full Text] [Related]

  • 12. Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.
    Goyal V, Grimwood K, Byrnes CA, Morris PS, Masters IB, Ware RS, McCallum GB, Binks MJ, Marchant JM, van Asperen P, O'Grady KF, Champion A, Buntain HM, Petsky H, Torzillo PJ, Chang AB.
    Lancet; 2018 Oct 06; 392(10154):1197-1206. PubMed ID: 30241722
    [Abstract] [Full Text] [Related]

  • 13. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A, RELIEF investigators.
    Lancet Respir Med; 2021 May 06; 9(5):476-486. PubMed ID: 33798455
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A.
    Lancet Respir Med; 2017 May 06; 5(5):390-400. PubMed ID: 28395936
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D, Bingham CO, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S.
    Lancet; 2017 Mar 25; 389(10075):1206-1217. PubMed ID: 28215362
    [Abstract] [Full Text] [Related]

  • 16. Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial.
    Lowe J, Gillespie D, Aboklaish A, Lau TMM, Consoli C, Babu M, Goddard M, Hood K, Klein N, Thomas-Jones E, Turner M, Hubbard M, Marchesi J, Berrington J, Kotecha S.
    Lancet Respir Med; 2024 Aug 25; 12(8):608-618. PubMed ID: 38679042
    [Abstract] [Full Text] [Related]

  • 17. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.
    Mohebbi N, Ritter A, Wiegand A, Graf N, Dahdal S, Sidler D, Arampatzis S, Hadaya K, Mueller TF, Wagner CA, Wüthrich RP.
    Lancet; 2023 Feb 18; 401(10376):557-567. PubMed ID: 36708734
    [Abstract] [Full Text] [Related]

  • 18. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
    Dinh A, Ropers J, Duran C, Davido B, Deconinck L, Matt M, Senard O, Lagrange A, Makhloufi S, Mellon G, de Lastours V, Bouchand F, Mathieu E, Kahn JE, Rouveix E, Grenet J, Dumoulin J, Chinet T, Pépin M, Delcey V, Diamantis S, Benhamou D, Vitrat V, Dombret MC, Renaud B, Perronne C, Claessens YE, Labarère J, Bedos JP, Aegerter P, Crémieux AC, Pneumonia Short Treatment (PTC) Study Group.
    Lancet; 2021 Mar 27; 397(10280):1195-1203. PubMed ID: 33773631
    [Abstract] [Full Text] [Related]

  • 19. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Chanan-Khan AA, Zaritskey A, Egyed M, Vokurka S, Semochkin S, Schuh A, Kassis J, Simpson D, Zhang J, Purse B, Foà R.
    Lancet Haematol; 2017 Nov 27; 4(11):e534-e543. PubMed ID: 28958469
    [Abstract] [Full Text] [Related]

  • 20. Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial.
    Ferrand RA, McHugh G, Rehman AM, Mujuru H, Simms V, Majonga ED, Nicol MP, Flaegstad T, Gutteberg TJ, Gonzalez-Martinez C, Corbett EL, Rowland-Jones SL, Kranzer K, Weiss HA, Odland JO, BREATHE Trial Group.
    JAMA Netw Open; 2020 Dec 01; 3(12):e2028484. PubMed ID: 33331916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.